Meeting
2020 ASCO Virtual Scientific Program
Preliminary safety, efficacy and pharmacokinetics (PK) results of KN026, a HER2 bispecific antibody in patients (pts) with HER2-positive metastatic breast cancer.
Authors
Dongmei Ji
Fudan University Shanghai Cancer Center, Shanghai, China
Dongmei Ji , Jian Zhang , Weina Shen , Yiqun Du , June Xu , Jing Yang , Xin Luo , Paul Kong , Fei Yang , Xi-Chun Hu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Clinical Trial Registration Number
NCT03619681
Citation
J Clin Oncol 38: 2020 (suppl; abstr 1041)
DOI
10.1200/JCO.2020.38.15_suppl.1041
Abstract #
1041
Poster Bd #
126
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Tucatinib, palbociclib, and letrozole in HR+/HER2+ metastatic breast cancer: Report of phase IB safety cohort.
First Author: Elena Shagisultanova
Poster
2023 ASCO Annual Meeting
Safety and efficacy of DB-1303 in patients with advanced/metastatic solid tumors: A multicenter, open-label, first-in-human, phase 1/2a study.
First Author: Kathleen N. Moore
Poster
2023 ASCO Annual Meeting
Preclinical and early clinical data of ZN-1041 in combination with trastuzumab deruxtecan to treat breast cancer with or without CNS metastases.
First Author: Carey K. Anders
Poster
2022 ASCO Annual Meeting
Early clinical safety and pharmacokinetics data of DZD1516, an BBB-penetrant selective HER2 inhibitor for the treatment of HER2-positive metastatic breast cancer.
First Author: Xichun Hu